Deucravacitinib, an Oral Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-controlled Trial (PSORIATYK SCALP). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s420, 2024. DOI: 10.25251/skin.8.supp.420. Disponível em: https://skin.dermsquared.com/skin/article/view/3088. Acesso em: 3 apr. 2025.